Domenico Germano, Vincenza Tinessa, Emiddio Barletta, Dino Turitto, Franco Muccio Carmine, Bruno Daniele
Oncology Unit, "A.O. G. Rummo", Benevento, Italy.
Neuroradiology Unit, "A.O.G. Rummo", Benevento, Italy.
World J Oncol. 2010 Dec;1(6):252-254. doi: 10.4021/wjon265w. Epub 2011 Jan 1.
Bevacizumab is a recombinant monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat metastatic cancers of the colon, rectum, kidney, and breast. Its side effects include proteinuria, hypertension, gastrointestinal perforations, and arterial emboli. Although these toxic effects are more frequent in patients with atherosclerosis, their pathophysiology remains unresolved. We observed that patients treated with bevacizumab who developed hypertension had similar clinical presentations and biologic features, leading us to propose a unique mechanism for the vascular side effects of bevacizumab. We report a case of a woman treated for her metastatic breast cancer with first line chemotherapy with Paclitaxel plus bevacizumab who developed a brain stroke.
贝伐单抗是一种针对血管内皮生长因子(VEGF)的重组单克隆抗体,用于治疗结肠癌、直肠癌、肾癌和乳腺癌的转移性癌症。其副作用包括蛋白尿、高血压、胃肠道穿孔和动脉栓塞。尽管这些毒性作用在动脉粥样硬化患者中更为常见,但其病理生理学仍未得到解决。我们观察到,接受贝伐单抗治疗并出现高血压的患者具有相似的临床表现和生物学特征,这使我们提出了贝伐单抗血管副作用的独特机制。我们报告一例接受一线化疗(紫杉醇加贝伐单抗)治疗转移性乳腺癌的女性发生中风的病例。